The pharmaceutical industry faced pressure and uncertainty in 2023 and that will likely continue in 2024, partially because of the implementation and evolution of the Inflation Reduction Act. Meanwhile, states are expected to continue their increasingly aggressive attempts to regulate drug pricing.
Originally published by Bloomberg Law - January 3, 2024.
Please see full publication below for more information.
